BenchSci, a leader in AI solutions for preclinical research and drug discovery, has announced a strategic partnership with Thermo Fisher Scientific Inc., recognized as a global leader in serving science. This collaboration is set to deliver AI-powered research tools and digital capabilities designed to enhance experimental design and bolster R&D productivity for scientists and researchers.

The partnership will utilize BenchSci’s ASCEND™ AI technology to create new AI-enabled tools. These include enterprise software solutions for scientific and analytical instruments, advanced web-based research literature searches, and optimized reagent selection. The goal of these tools is to assist scientists and researchers in interpreting large scientific datasets, designing effective experiments, reviewing published literature, and optimizing laboratory resources.

“BenchSci’s technology acts as an AI assistant for scientists, leveraging a proprietary biomedical knowledge graph and machine learning models to decode scientific evidence and uncover biological insights. This partnership will expand what’s possible for researchers everywhere,” said Liran Belenzon, CEO and co-founder of BenchSci. He emphasized that combining their AI expertise with Thermo Fisher's extensive lab equipment and services will create new opportunities for scientists across the life sciences ecosystem.

“AI is unlocking a new era of scientific possibility, and our partnership with BenchSci will help our customers accelerate their important work,” stated Gianluca Pettiti, executive vice president and president, Life Sciences, Diagnostics, and Applied at Thermo Fisher Scientific. He noted that by merging their global scale and innovation leadership with BenchSci’s advanced AI capabilities, they aim to transform their customers’ ability to model science in silico, facilitating a quicker and more cost-effective journey from scientific ideas to approved medicines.

BenchSci is on a mission to significantly speed up the R&D process for life-saving drugs, applying AI to better understand disease biology throughout the drug discovery pipeline. Their ASCEND platform serves as a scalable AI assistant for preclinical organizations, enhancing productivity across various therapeutic areas. Supported by leading investors, including Generation Investment Management and Google’s AI fund, BenchSci has successfully raised over $200 million and is recognized among top pharmaceutical companies and research centers globally. For further details about BenchSci, visit www.benchsci.com.